Since 2017, the St Gallen consensus meeting have clearly highlighted the neoadjuvant approach as the preferred treatment option in HER2 + BC equal or larger than 2 cm or with axillary lymph node involvement [29]. This evidence concerns the gene ERBB2 and breast cancer.